

GEMS: Final Presentation

Operationalizing a ‘functional potential score’ (FPS) to prioritize GWAS variants for experimental studies

Dhruv Jain (jaind3@mskcc.org)

Mentor: Dr. Matthew F. Buas,

Date: August-10-2023



Memorial Sloan Kettering
Cancer Center

Outline

- Introduction
- Approach
- Results
- Conclusion

Introduction



Background of Research

Genome-wide association studies (GWAS)

- GWAS identifies genetic links to diseases like cancer, diabetes, cardiovascular disease.
- Researchers analyze markers in individuals, revealing genetic variants tied to susceptibility.
- This aids risk assessment, prevention, and treatment strategies.

What is problem?


- Statistical associations in GWAS do not reveal biological mechanisms
- Most GWAS signals are located in “non-coding regions”, suggesting regulatory functions.
- The lead SNP in each GWAS locus is often correlated with multiple other variants, making it difficult to determine the true functional or causal signal.
- Laboratory follow-up is time-consuming, labor-intensive, and costly

Tools Exists like Haploreg, RegulomeDB, FUMA, & FORGE

Limitations:

- Incorporation of new or updated data inputs
- Customization for prioritizing annotation calls in specific tissues.
- Weighting and aggregation of inputs into a composite score.

Associated variant set (AVS)



- Lead SNP (peak) often correlated with multiple other neighboring SNPs
- Any of these variants could be the functional /causal signal underlying the association


Approach



Function Potential Score (FPS)

A composite SNP-level metric to summarize overall evidence for functional/regulatory potential.

- A. DNA sequence
- B. Chromatin Accessibility
- C. Histone Modification
- D. SNP ~ Gene Paring



GENERAL ARTICLE


Prioritization and functional analysis of GWAS risk loci for Barrett's esophagus and esophageal adenocarcinoma

Jianhong Chen^{1,†}, Mourad Wagdy Ali^{2,†}, Li Yan^{3,†}, Shruti G. Dighe¹, James Y. Dai⁴, Thomas L. Vaughan^{4,5}, Graham Casey^{2,5,*} and Matthew F. Buas^{1,5,*}

Part A ~ SEQUENCE

1. Sequence
Context

dbSNP




2. Extensive
conservation

Zoonomia

-20	1	20	
CTTTTCAAGG	AGTATTTTCT	ATGAACGAGT	TAGACGGCAT
CATTGCAAAG	GGAATAATCT	ATGAACGCAA	TAATTATTGA
CATTTTCAGG	ATAACTTTCT	ATGAAAGTAA	ACTTAATACT
GAAAAGAAAT	CGAGGC AAAA	ATGAGCAAAG	TCAGACTCGC
TGCAAAAAAA	GGAAGACCAT	ATGCTTGACG	CTCAAACCAT
TTTTTGTGGA	GAAGACGCGT	GTGATTGTTA	AACGACCCGT

3.
Transcription
Factor motifs

SNP2TFBS



Part B ~ CHROMATIN ACCESSIBILITY

4. ATAC – seq



Cancer
Genome Atlas
(TCGA)

5. DNase |
Hypersensitivity

Roadmap/
ENCODE

6. TF chip-seq

ReMap2022



Part C ~ HISTONE MODIFICATIONS

7. HMM -15



Roadmap/
ENCODE

8. Enhancer




Roadmap/
ENCODE

9. Super
Enhancer


Roadmap/
ENCODE



Part D SNP ~ GENE PAIRINGS



Assigning 0/1 calls to SNPs ~ overlap with annotation windows



<u>SNP</u>	<u>Call</u>
1	1
2	0
3	0
4	0
5	1
6	1
7	0

- Browser Extensible data .BED
- Chr, start, end position.



Theoretical Framework

Feature	Call	Value	Weight	Feature Score (FS)
1	c1	0/1	W1	W1 × c1
2	c2	0/1	W2	W2 × c2
3	c3	0/1	W3	W3 × c3
<hr/>				
4	c4_1	0/1	W4_1	W4_1 × c4_1 + W4_2 × c4_2 + W4_3 × c4_3
	c4_2	0/1	W4_2	
	c4_3	0/1	W4_3	
<hr/>				
5	c5_1	0/1	W5_1	W5_1 × c5_1 + W5_2 × c5_2 + W5_3 × c5_3
	c5_2	0/1	W5_2	
	c6_3	0/1	W5_3	
<hr/>				
.. ..				
12	c12_1	0/1	W12_1	W12_1 × c12_1 + W12_2 × c12_2 + W12_3 × c12_3
	c12_2	0/1	W12_2	
	c12_3	0/1	W12_3	

[K,O]	Call	Value
[1,0]	ci_1	1
	ci_2	0
	ci_3	0
[1,1]	ci_1	0
	ci_2	1
	ci_3	0
[0,1]	ci_1	0
	ci_2	0
	ci_3	1
[0,0]	ci_1	0
	ci_2	0
	ci_3	0

$$FPS = \sum_{j=0}^{j=3} W_j \cdot c_j + \sum_{j=4}^{j=12} \{(W_{j-1} \cdot c_{j-1}) + (W_{j-2} \cdot c_{j-2}) + (W_{j-3} \cdot c_{j-3})\}$$

Experimental data for model building

ARTICLE

Massively parallel reporter assays and variant scoring identified functional variants and target genes for melanoma loci and highlighted cell-type specificity

Authors

Erping Long, Jinhua Yin, Karen M. Funderburk, ...,
Stephen J. Chanock, Kevin M. Brown, Jiyeon Choi

1. Massively parallel reporter assay (MPRA) data on 1,992 variants from 54 melanoma GWAS loci
2. 285 SNPs showed allelic-specific transcriptional activity in melanoma/melanocyte cell lines (FDR<0.01)
3. Smaller subsets of the 285 SNPs showed stronger allelic differences (%): 114 ($\geq 10\%$) and 65 ($\geq 15\%$)
4. SNPs randomly split to training (2/3) & testing sets (1/3)
5. MPRA functional calls for each SNP were merged with FPS calls and used for model building (training set)

Flow chart

1

Step 1:

Make feature calls
for all SNPs

2

Step 2:

Use Training set to
select optimal λ
(5-fold CV)

3

Step 3:

Build LASSO model
using selected λ^*
(entire Training set)

4

Step 4:

Extract model
coefficients

5

Step 5:

Run model using
Testing data and
assess performance

- λ (lambda) is the regularization parameter that controls the amount of shrinkage applied to the coefficients.
- Higher values of lambda lead to more aggressive shrinkage and a sparser model
- Use cross-validation to select optimal lambda
- Goal ~ reduce overfitting




Conclusion




Lambda Selection

1




Optimal $\lambda \rightarrow 0.02118$

2



Optimal $\lambda \rightarrow 0.0080$


3



Optimal $\lambda \rightarrow 0.00621$


Lasso Coefficients

- LASSO model indicates that certain annotation data inputs were most predictive of experimentally-determined SNP regulatory function:
- Seq conservation (c2n)
- Dnase Seq (c5_1, c5n_K)
- TF-ChIP-seq (c6n_K, c6_3)



ROC CURVE (Receiver operating characteristic)

- $AUC (ad15) = 0.71$
- $AUC (ad10) = 0.67$
- $AUC (ADS) = 0.54$



Future Work

- Lab work can use this SNPs tell scientists whether you will react positively or not to a specific treatment.
- Identifying functional/causal variants and risk genes at GWAS loci remains a critical challenge for downstream clinical translation
- Collaborate with clinicians to access clinical samples and validate the associations between genomic regions and clinical outcomes in real patient populations.

Expressing Gratitude



Mentor: Dr. Matthew Buas

- Your guidance has been my guiding light, aiding me through challenges and growth.



Lab Assistant: Dr. Shiv Verma Prakash

- Your expertise and patience have been invaluable in my lab experiences.

Fellow Interns and their mentors

- Your camaraderie and support have enriched my perspectives and journey."

Thank you for your unwavering encouragement and contributions.



Memorial Sloan Kettering
Cancer Center